Abstract:Background Previous genome-wide association studies (GWAS) have identified several risk genes for stroke; however, it remains unclear how they confer risk for the disease. We conducted an integrative analysis to identify candidate genes for stroke and stroke subtypes by integrating blood-derived multi-omics data with genetic data. Method We systematically integrated the latest stroke GWAS database (73,652 patients and 1,234,808 controls) with human plasma proteomes (N=7,213) and performed proteome-wide association studies (PWAS), Mendelian randomization (MR), Bayesian colocalization analysis, and transcriptome-wide association study (TWAS) to prioritize genes that associate the risk of stroke and its subtypes with their expression and protein abundance in plasma. Cell-type specificity and functional enrichment analysis using single-cell RNA sequencing (scRNA-seq) and Gene Ontology (GO) databases were then performed to select target genes. A two-step MR analysis was followed to explore the potential mechanisms. Results We found that the protein abundance of seven genes ( MMP12, F11, SH3BGRL3, ENGASE, SCARA5, SWAP70, and SPATA20 ) in the plasma was associated with stroke and its subtypes, with six genes ( MMP12, F11, SH3BGRL3, SCARA5, SWAP70, and SPATA20 ) causally related with stroke and its subtypes (P < 0.05/proteins identified for PWAS; P < 0.05/8 for MR; posterior probability of hypothesis 4 ≥ 75 % for Bayesian colocalization). The effect of F11, SH3BGRL, SPATA20, and SWAP70 on each subtype was mediated by Factor XI inhibitors (FXI), atrial fibrillation, T2D, and SBP respectively (p<0.05). We also found that SCARA5 and SWAP70 were related to stroke and ischemic stroke at the transcriptome level. Conclusions Our present proteomic findings have identified new causal genes in the pathogenesis of stroke, which may offer potential future therapeutic targets for stroke prevention. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement This study was partially supported by grants from the National Natural Science Foundation of China (No. 81400979 and 81870931), the SanHang Program of the Naval Medical University, and the ?Climbing? program of Changhai Hospital. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: NONE I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes All data in the manuscript is truly usable

Systematic Mendelian randomization using the human plasma proteome to discover potential therapeutic targets for stroke

Multi-omics combined to investigate potential druggable therapeutic targets for stroke: A systematic Mendelian randomization study and transcriptome verification

Plasma Proteomes and Genome-Wide Association Data for Causal Protein Identification in Stroke

Identification of Potential Therapeutic targets for Stroke and Its Subtypes by Integrating Proteomes and Genetics from Human Plasma

Protein Identification for Stroke Progression via Mendelian Randomization in Million Veteran Program and UK Biobank

Systematic Druggable Genome‐Wide Mendelian Randomization Identifies Therapeutic Targets for Functional Outcome after Ischemic Stroke

Assessing the causal effect of genetically predicted metabolites and metabolic pathways on stroke

Comprehensive mendelian randomization analysis of plasma proteomics to identify new therapeutic targets for the treatment of coronary heart disease and myocardial infarction

Plasma proteome mediate the impact of PM2.5 on stroke: A 2-step Mendelian randomization study

Causal relationship between genetically determined plasma metabolites and stroke: A two sample Mendelian randomization study

Plasma protein alterations during human large vessel stroke: A controlled comparison study

Novel Drug Targets for Atrial Fibrillation Identified Through Mendelian Randomization Analysis of the Blood Proteome

Leveraging Mendelian randomization to inform drug discovery and development for ischemic stroke

Plasma Proteomic Insights for Identification of Novel Predictors and Potential Drug Targets in Atrial Fibrillation: A Prospective Cohort Study and Mendelian Randomization Analysis

Genetically predicted plasma levels of amino acids and stroke risk: a Mendelian randomization study

Proteome-Wide Mendelian Randomization Analysis Identified Potential Drug Targets for Atrial Fibrillation

Proteome-wide Mendelian Randomization Identifies Causal Plasma Proteins in Venous Thromboembolism Development

The interplay between cytokines and stroke: a bi-directional Mendelian randomization study

Genetic determinants of circulating metabolites and the risk of stroke and its subtypes

Phenome-wide Mendelian randomization mapping the influence of the plasma proteome on complex diseases

Proteomic and genomic evaluation of plasma protein biomarkers for atrial fibrillation